REC-4881 (4 mg QD) showed rapid reductions in total polyp burden with 75% of patients experiencing reductions after 12 weeks of treatment.
82% of patients maintained a durable reduction in polyp burden at Week 25, 12 weeks post-treatment.
REC-4881 demonstrated safety profile consistent with MEK1/2 inhibition, with majority of adverse events being Grade 1 or 2.
Clinical Activity
75% of patients had reductions in total polyp burden after 12 weeks of treatment.
Durable Reductions
82% of patients maintained reductions at Week 25, with a 53% median decrease from baseline.
Safety Profile
Majority of treatment-related adverse events were Grade 1 or 2, with no Grade ≥4 TRAEs reported to date.
First Clinical Validation of Recursion OS
REC-4881's positive results demonstrate the potential of unbiased phenotypic insights to develop novel therapeutics for FAP.
- REC-4881's positive Phase 1b/2 results provide hope for the FAP community facing a lack of approved medical therapies.
- Identification of MEK1/2 inhibition as a specific mechanism for FAP treatment opens new avenues for research and therapeutic development.
REC-4881's Phase 2 results offer promising outcomes for FAP patients, indicating a potential non-surgical option for polyp burden reduction and disease management.